TrialBreast cancer research and treatment2022

Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial.

Tamas Hickish et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.